

# Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

## Institute of Cancer Research

RRID:SCR\_003912

Type: Tool

---

### Proper Citation

Institute of Cancer Research (RRID:SCR\_003912)

---

### Resource Information

**URL:** <http://www.icr.ac.uk/>

**Proper Citation:** Institute of Cancer Research (RRID:SCR\_003912)

**Description:** Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR's own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology.

**Abbreviations:** ICR

**Synonyms:** The Institute of Cancer Research

**Resource Type:** institution

**Keywords:** clinical, medical, oncology

**Related Condition:** Cancer

**Resource Name:** Institute of Cancer Research

**Resource ID:** SCR\_003912

**Alternate IDs:** nlx\_158259, grid.18886.3f, Wikidata: Q6039999, ISNI: 0000 0001 1271 4623

**Alternate URLs:** <https://ror.org/043jzw605>

**Record Creation Time:** 20220129T080221+0000

**Record Last Update:** 20260821T193711+0000

---

## Ratings and Alerts

No rating or validation information has been found for Institute of Cancer Research.

No alerts have been found for Institute of Cancer Research.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Swerdlow AJ, et al. (2022) Risk of breast cancer in men in relation to weight change: A national case-control study in England and Wales. *International journal of cancer*, 150(11), 1804.

Gurden MD, et al. (2018) Aurora B prevents premature removal of spindle assembly checkpoint proteins from the kinetochore: A key role for Aurora B in mitosis. *Oncotarget*, 9(28), 19525.

Faisal A, et al. (2017) Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy. *British journal of cancer*, 116(9), 1166.

Ahdesm??ki MJ, et al. (2017) Prioritisation of structural variant calls in cancer genomes. *PeerJ*, 5, e3166.

Dolly SO, et al. (2017) RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. *British journal of cancer*, 117(7), 954.

Natrajan R, et al. (2016) Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis. *PLoS medicine*, 13(2), e1001961.

Maxwell KN, et al. (2016) Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American journal of human genetics*, 98(5), 801.

Rankin SS, et al. (2016) Synthesis of a Ribose-Incorporating Medium Ring Scaffold via a Challenging Ring-Closing Metathesis Reaction. *European journal of organic chemistry*, 2016(26), 4496.

Khankari NK, et al. (2016) Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. PLoS medicine, 13(9), e1002118.

Lamber EP, et al. (2013) Structural insights into the mechanism of phosphoregulation of the retinoblastoma protein. PloS one, 8(3), e58463.

Podesta JE, et al. (2011) Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia research, 35(9), 1273.

Kote-Jarai Z, et al. (2010) Mutation analysis of the MSMB gene in familial prostate cancer. British journal of cancer, 102(2), 414.